Document Detail

Malaria Vaccine Trials - Beyond Efficacy End Points.
MedLine Citation:
PMID:  23136910     Owner:  NLM     Status:  Publisher    
Plasmodium falciparum infection, malaria, continues to cause more than 1 million childhood deaths each year.(1) In addition, millions of nonlethal infections affect communities on an economic basis and inhibit children from reaching their full developmental potential.(2) The creation of an effective vaccine has been a long-sought, elusive goal. The first results of the phase 3 trial of the candidate malaria vaccine RTS,S/AS01, which is being conducted in seven African countries, were reported for children 5 to 17 months of age at enrollment, with a vaccine efficacy of 56% against all clinical malaria infections and 47% against severe malaria during a . . .
Johanna P Daily
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-9
Journal Detail:
Title:  The New England journal of medicine     Volume:  -     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
Next Document:  Meta-analysis: Efficacy of small bowel preparation for small bowel video capsule endoscopy.